Julia Vax focuses her practice on corporate and securities laws in representing emerging growth and public companies, primarily in the life sciences and technology sectors, from formation and early-stage capital raising to publicly traded entities. Ms. Vax has advised clients in the biopharmaceutical, genomics, medical device, diagnostics, Internet and digital media, software, IP telephony, telecommunications and financial services sectors in all aspects of their corporate development and in connection with a broad range of financing and strategic transactions. Ms. Vax has extensive experience in IPOs, Rule 144A transactions, shelf registrations, private placements, including PIPE transactions and venture capital financings, as well as in executive compensation, corporate governance and SEC reporting and compliance for public companies. She has been involved in numerous public and private financing transactions representing companies, investors, underwriters and placement agents.
Ms. Vax is a faculty member at the Center for International Legal Studies and has taught US corporate securities laws at the University of Tartu, Estonia, School of Law, as a Visiting Professor in the Fall 2017.